Monoclonal Antibodies

Therapidcommercializationofmonoclonalantibodies(mAbs)representsastaggering$180billionpharmacologicalbreakthroughintargetedmolecularimmunotherapy.Unlikebroad-spectrumchemotherapeuticagentsthatindiscriminatelytoxifybothmalignantandhealthyrapidlydividingsomaticcells,mAbsareengineeredtobindspecificallytouniqueantigenicepitopesexpressedexclusivelyonthecellularmembranesoftargetedpathogensorneoplastictumors.Theproductionbeginsbyimmunizingatransgenicmurinehostwiththetargetantigen,stimulatingitsB-lymphocytestoproducespecificimmunoglobulins.ThesehighlyspecializedB-cellsareextractedfromthespleenandfusedwithimmortalizedmyelomacells,creatingarobusthybridomacelllinecapableofinfinitereplicationwhilecontinuouslysecretingthedesiredantibody.Topreventthehumanimmunesystemfromrejectingthetherapeuticprotein,geneticengineersutilizerecombinantDNAtechnologytohumanizetheantibody,replacing95%ofthemurineaminoacidsequenceswithhumanIgGframeworks,effectivelyreducingsevereimmunogenicresponseslikeanaphylaxis.Pharmacologically,mAbsexerttheirtherapeuticefficacythroughmultiplecomplexmechanisms.Trastuzumab(Herceptin),forexample,bindsdirectlytotheHumanEpidermalGrowthFactorReceptor2(HER2),whichisaggressivelyoverexpressedinroughly20%ofinvasivebreastcarcinomas.Thisbindingneutralizesthereceptor'sdimerization,activelyarrestingtheintracellularphosphatidylinositol3-kinase(PI3K)signalingcascadeandplungingthemalignantcellintotargetedapoptosis.Furthermore,theFcregionoftheboundantibodyrecruitsnaturalkiller(NK)cellsandmacrophages,initiatingviolentantibody-dependentcellularcytotoxicity(ADCC).CurrentPhaseIIItrialsarefiercelyoptimizingbispecificantibodies(bsAbs),engineeredtobindtwodistincttargetssimultaneously,physicallybridgingacytotoxicT-celldirectlytoatumorcelltomaximizelocalizedlethality.